cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25390/caryinstitute.7469573
title: Cary Environmental Monitoring Program UVB Data 2000-2017

description: The Cary Institute of Ecosystem Studies Environmental Monitoring Program is a long-term data collection program designed to understand how the environment changes over time. The program includes monitoring of climate including temperature and precipitation, as well as variables related to air pollution, such as acid deposition and ozone, and water pollution and other streamwater chemistry. Our solar radiation monitoring includes diffuse and global photosynthetically active radiation (PAR), diffuse and global shortwave radiation, net radiation and UV. Long-term monitoring of solar radiation provides us with an understanding of atmospheric energy dynamics, which can affect natural and human systems. The Cary Institute of Ecosystem Studies, Environmental Monitoring Program furnishes data under the following conditions: The data have received quality assurance scrutiny by our program, and, although we are confident of the accuracy of these data, the Cary Institute will not be held liable for errors in these data. Data are subject to change resulting from updates in data screening or models used. Data citation: The following is a standard citation for referencing data from the Cary Institute of Ecosystem Studies, Environmental Monitoring Program:<br>Cary Institute of Ecosystem Studies, Environmental Monitoring Program. 2008 (or current year). Cary Institute of Ecosystem Studies, Box AB, Millbrook, NY 12545, www.caryinstitute.org. <br>Those wishing to publish data from the Cary Institute of Ecosystem Studies, Environmental Monitoring Program are encouraged to contact Data Manager Vicky Kelly, kellyv@caryinstitute.org.
DOI: 10.6084/m9.figshare.7469636.v1
title: WP - zadanie grupowe - Kuchta Małgorzata

description: zdanie grupowe - WP - Kuchta Małgorzata, Mularczyk Kamil, Latus Ola, Morgaś Martyna, Kapusz Julia- UE Wrocław<br>
DOI: 10.7284/122365
title: TSG (Thermosalinograph) data collected during research cruise MGL1508 using a Sea-Bird SBE-21 instrument system onboard the platform RV Marcus G. Langseth

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.25390/caryinstitute.7469573.v1
title: Cary Environmental Monitoring Program UVB Data 2000-2017

description: The Cary Institute of Ecosystem Studies Environmental Monitoring Program is a long-term data collection program designed to understand how the environment changes over time. The program includes monitoring of climate including temperature and precipitation, as well as variables related to air pollution, such as acid deposition and ozone, and water pollution and other streamwater chemistry. Our solar radiation monitoring includes diffuse and global photosynthetically active radiation (PAR), diffuse and global shortwave radiation, net radiation and UV. Long-term monitoring of solar radiation provides us with an understanding of atmospheric energy dynamics, which can affect natural and human systems. The Cary Institute of Ecosystem Studies, Environmental Monitoring Program furnishes data under the following conditions: The data have received quality assurance scrutiny by our program, and, although we are confident of the accuracy of these data, the Cary Institute will not be held liable for errors in these data. Data are subject to change resulting from updates in data screening or models used. Data citation: The following is a standard citation for referencing data from the Cary Institute of Ecosystem Studies, Environmental Monitoring Program:<br>Cary Institute of Ecosystem Studies, Environmental Monitoring Program. 2008 (or current year). Cary Institute of Ecosystem Studies, Box AB, Millbrook, NY 12545, www.caryinstitute.org. <br>Those wishing to publish data from the Cary Institute of Ecosystem Studies, Environmental Monitoring Program are encouraged to contact Data Manager Vicky Kelly, kellyv@caryinstitute.org.
DOI: 10.6084/m9.figshare.7469453
title: p = 0.1

description: pressure = 0.1<br>
DOI: 10.6084/m9.figshare.7469570
title: Data File (IT Gov.Inno,OP).csv

description: This data is about IT governance, Innovation and Organizational Performance in public sector organizations of Pakistan
DOI: 10.6084/m9.figshare.7469570.v1
title: Data File (IT Gov.Inno,OP).csv

description: This data is about IT governance, Innovation and Organizational Performance in public sector organizations of Pakistan
DOI: 10.6084/m9.figshare.7469453.v1
title: p = 0.1

description: pressure = 0.1<br>
DOI: 10.7284/122372
title: GNSS (Global Navigation Satellite System) data collected during research cruise MGL1509 using a C&C C-Nav 3050 instrument system onboard the platform RV Marcus G. Langseth

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.6084/m9.figshare.7469438
title: Association of hyperuricemia and pulmonary hypertension: A systematic review and meta-analysis

description: <b>Objectives:</b> To investigate the association of hyperuricemia with pulmonary hypertension (PH) in term of subsequent development, severity, and prognosis of PH. <b>Methods:</b> The authors systematically reviewed articles from databases and conducted meta-analyses as follows: (1) association of serum uric acid (UA) levels with the presence of PH; (2) association between serum UA levels and subsequent development of PH, in terms of odds ratio of the development of PH; and (3) association of serum UA levels with severity and prognosis of PH, in terms of pulmonary arterial pressure and hazard ratio of death. <b>Results:</b> Twenty-six studies published between 1999 and 2017 were included. The level of serum UA was higher in subjects with PH than subjects without PH and this finding was observed regardless of status of diuretics use or renal function. The odds ratio of the development of PH was 2.32 (95% CI, 1.05–5.15) in subjects with hyperuricemia. Pulmonary arterial pressure among subjects with PH was also higher in subjects with hyperuricemia than subjects with normouricemia. There was a 19% increased hazard ratio of death (95% CI, 1.06–1.33) among patients with PH who had hyperuricemia. <b>Conclusion:</b> Hyperuricemia is associated with the subsequent development, worse severity and poor prognosis of PH.
DOI: 10.7284/122376
title: GNSS (Global Navigation Satellite System) data collected during research cruise MGL1509 using a C&C C-Nav 2000 instrument system onboard the platform RV Marcus G. Langseth

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.6084/m9.figshare.7469438.v2
title: Association of hyperuricemia and pulmonary hypertension: A systematic review and meta-analysis

description: <b>Objectives:</b> To investigate the association of hyperuricemia with pulmonary hypertension (PH) in term of subsequent development, severity, and prognosis of PH. <b>Methods:</b> The authors systematically reviewed articles from databases and conducted meta-analyses as follows: (1) association of serum uric acid (UA) levels with the presence of PH; (2) association between serum UA levels and subsequent development of PH, in terms of odds ratio of the development of PH; and (3) association of serum UA levels with severity and prognosis of PH, in terms of pulmonary arterial pressure and hazard ratio of death. <b>Results:</b> Twenty-six studies published between 1999 and 2017 were included. The level of serum UA was higher in subjects with PH than subjects without PH and this finding was observed regardless of status of diuretics use or renal function. The odds ratio of the development of PH was 2.32 (95% CI, 1.05–5.15) in subjects with hyperuricemia. Pulmonary arterial pressure among subjects with PH was also higher in subjects with hyperuricemia than subjects with normouricemia. There was a 19% increased hazard ratio of death (95% CI, 1.06–1.33) among patients with PH who had hyperuricemia. <b>Conclusion:</b> Hyperuricemia is associated with the subsequent development, worse severity and poor prognosis of PH.
DOI: 10.7284/122377
title: Gravimeter data collected during research cruise MGL1509 using a Bell BGM-3 instrument system onboard the platform RV Marcus G. Langseth

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.7284/122375
title: Gyrocompass data collected during research cruise MGL1509 using a Kongsberg Simrad GC80 instrument system onboard the platform RV Marcus G. Langseth

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.6084/m9.figshare.7469438.v1
title: Association of hyperuricemia and pulmonary hypertension: A systematic review and meta-analysis

description: <b>Objectives:</b> To investigate the association of hyperuricemia with pulmonary hypertension (PH) in term of subsequent development, severity, and prognosis of PH. <b>Methods:</b> The authors systematically reviewed articles from databases and conducted meta-analyses as follows: (1) association of serum uric acid (UA) levels with the presence of PH; (2) association between serum UA levels and subsequent development of PH, in terms of odds ratio of the development of PH; and (3) association of serum UA levels with severity and prognosis of PH, in terms of pulmonary arterial pressure and hazard ratio of death. <b>Results:</b> Twenty-six studies published between 1999 and 2017 were included. The level of serum UA was higher in subjects with PH than subjects without PH and this finding was observed regardless of status of diuretics use or renal function. The odds ratio of the development of PH was 2.32 (95% CI, 1.05–5.15) in subjects with hyperuricemia. Pulmonary arterial pressure among subjects with PH was also higher in subjects with hyperuricemia than subjects with normouricemia. There was a 19% increased hazard ratio of death (95% CI, 1.06–1.33) among patients with PH who had hyperuricemia. <b>Conclusion:</b> Hyperuricemia is associated with the subsequent development, worse severity and poor prognosis of PH.
DOI: 10.7284/122373
title: INS (Inertial Navigation System) data collected during research cruise MGL1509 using a Kongsberg Seapath 200 instrument system onboard the platform RV Marcus G. Langseth

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.7284/122378
title: INS (Inertial Navigation System) data collected during research cruise MGL1509 using a Applanix POS/MV-320 V3 instrument system onboard the platform RV Marcus G. Langseth

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.6084/m9.figshare.7468505
title: Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment

description: <b>Background:</b> Guidelines recommend primary prophylactic use of colony-stimulating factor (PP-CSF) when risk of febrile neutropenia (FN) – based on chemotherapy and patient risk factors – is high. Whether and how PP-CSF use may have changed over time (e.g. due to guideline revisions, increasing use of myelosuppressive regimens, controversy regarding inappropriate CSF use), and whether there has been a concomitant change in the incidence of FN, is unknown. <b>Methods:</b> A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use. <b>Results:</b> The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (&gt;96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF. <b>Conclusions:</b> Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy.
DOI: 10.6084/m9.figshare.7467776
title: Figshare data.xlsx

description: Data for Germino, Moser, and Sands in Ecological Applications"Adaptive variation, including local adaptation, requires decades to become evident in common gardens"
DOI: 10.7284/122380
title: Meteorological Station data collected during research cruise MGL1509 using a RM Young 26700 instrument system onboard the platform RV Marcus G. Langseth

description: Original (unprocessed) data collected during a Field_expedition
DOI: 10.6084/m9.figshare.7467773
title: Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes

description: <b>Objective:</b> The LixiLan clinical trials of insulin glargine (iGlar)/lixisenatide fixed-ratio combination (iGlarLixi) investigated the safety and efficacy of iGlarLixi versus iGlar: LixiLan-O (NCT02058147) in patients with type 2 diabetes (T2D) inadequately controlled on oral antidiabetes drugs (OADs) and LixiLan-L (NCT02058160) in patients with T2D inadequately controlled on basal insulin ± OADs. In these two trials, both iGlar and iGlarLixi were titrated to a maximum (capped) dose of 60 units. We evaluated whether this may have affected the reported glycemic efficacy of iGlar, and the glycemic differences observed between treatment with iGlarLixi and iGlar. <b>Methods:</b> The efficacy of iGlar under uncapped conditions was simulated in a two-step approach. First, a model characterizing the relationship between iGlar dose and fasting self-measured plasma glucose (f-SMPG) was developed. Then, the relationship between glycated hemoglobin A1<sub>c</sub> (A1C) and f-SMPG was established to translate simulated f-SMPG responses to A1C responses. <b>Results:</b> Most patients achieved stable f-SMPG at ∼60 units/day, with no further reduction with increasing insulin dose. In comparisons of observed/capped and simulated/uncapped changes in mean A1C from baseline to Week 30, iGlarLixi consistently demonstrated treatment benefit compared with iGlar. Uncapping resulted in a slightly higher mean iGlar dose in both LixiLan-O (+0.72 units) and LixiLan-L (+2.1 units), without marked impact on f-SMPG or A1C change from baseline. <b>Conclusion:</b> Uncapping the iGlar dose in LixiLan-O and LixiLan-L would not have led to significant improvements in mean A1C reduction in the iGlar arm, supporting the conclusion that iGlarLixi provides additional, clinically relevant glycemic control versus iGlar alone.
DOI: 10.6084/m9.figshare.7467746
title: PTR-ToF-MS data

description: Volatiles were analyzed with a PTR-ToF-MS 8000 (IoniconAnalytik GmbH, Innsbruck, Austria) using H<sub>3</sub>O<sup>+</sup> as reagent ion for the proton transfer reaction. The reaction takes place between H<sub>3</sub>O<sup>+</sup> ions and all the biogenic or anthropogenic VOCs having a proton affinity higher than that of water (165.2 kcal mol<sup>−1</sup>). Separation of single ions happens accordingly to their mass to charge (<i>m/z</i>) ratio. Drift applied voltage was set at 600 V, temperature at 110 °C, and pressure at 2.25 mbar. For each sample, about 6 grams of material was transferred in a glass jar provided with a special lid that allowed Teflon connection to a zero-air generator (inlet) and the PTR-ToF system (outlet). The head space was then measured by direct injection into the PTR-ToF drift tube inlet for 150 seconds, after respectively 1 and 20 min of exposure. Preliminary measurements on an empty jar were run before every experiment and used for background subtraction. All mass spectra up to <i>m/z</i> = 315 were simultaneously detected and recorded with 1 s as integration time. Internal calibration was based on <i>m</i>/<i>z</i> = 18.0338 (NH<sub>4</sub><sup>+</sup>), <i>m/z</i> = 21.0202 (H<sub>3</sub><sup>18</sup>O<sup>+</sup>) and <i>m/z</i> = 29.9974 (NO<sup>+</sup>).
DOI: 10.6084/m9.figshare.7468505.v1
title: Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010-2016: a longitudinal assessment

description: Background: Guidelines recommend primary prophylactic use of colony-stimulating factor (PP-CSF) when risk of febrile neutropenia (FN)—based on chemotherapy and patient risk factors—is high. Whether and how PP-CSF use may have changed over time (e.g., due to guideline revisions, increasing use of myelosuppressive regimens, controversy regarding inappropriate CSF use), and whether there has been a concomitant change in the incidence of FN, is unknown. Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. Study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung, or ovaries or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high-risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010-2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use. Results: Study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%), or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (&gt;96% across quarters). PP-CSF administration on same day as chemotherapy ranged from 8-11% until Q12015, and increased to 64% by Q42016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95%CI: 2.3-3.0) to 3.7% (95%CI: 3.1-4.3) among those who did not receive PP-CSF, and was 2.6% (95%CI: 2.5-2.7) across quarters among those who received PP-CSF. Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high-risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy.
DOI: 10.6084/m9.figshare.7467746.v1
title: PTR-ToF-MS data

description: Volatiles were analyzed with a PTR-ToF-MS 8000 (IoniconAnalytik GmbH, Innsbruck, Austria) using H<sub>3</sub>O<sup>+</sup> as reagent ion for the proton transfer reaction. The reaction takes place between H<sub>3</sub>O<sup>+</sup> ions and all the biogenic or anthropogenic VOCs having a proton affinity higher than that of water (165.2 kcal mol<sup>−1</sup>). Separation of single ions happens accordingly to their mass to charge (<i>m/z</i>) ratio. Drift applied voltage was set at 600 V, temperature at 110 °C, and pressure at 2.25 mbar. For each sample, about 6 grams of material was transferred in a glass jar provided with a special lid that allowed Teflon connection to a zero-air generator (inlet) and the PTR-ToF system (outlet). The head space was then measured by direct injection into the PTR-ToF drift tube inlet for 150 seconds, after respectively 1 and 20 min of exposure. Preliminary measurements on an empty jar were run before every experiment and used for background subtraction. All mass spectra up to <i>m/z</i> = 315 were simultaneously detected and recorded with 1 s as integration time. Internal calibration was based on <i>m</i>/<i>z</i> = 18.0338 (NH<sub>4</sub><sup>+</sup>), <i>m/z</i> = 21.0202 (H<sub>3</sub><sup>18</sup>O<sup>+</sup>) and <i>m/z</i> = 29.9974 (NO<sup>+</sup>).
DOI: 10.6084/m9.figshare.7467773.v2
title: Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes

description: <b>Objective:</b> The LixiLan clinical trials of insulin glargine (iGlar)/lixisenatide fixed-ratio combination (iGlarLixi) investigated the safety and efficacy of iGlarLixi versus iGlar: LixiLan-O (NCT02058147) in patients with type 2 diabetes (T2D) inadequately controlled on oral antidiabetes drugs (OADs) and LixiLan-L (NCT02058160) in patients with T2D inadequately controlled on basal insulin ± OADs. In these two trials, both iGlar and iGlarLixi were titrated to a maximum (capped) dose of 60 units. We evaluated whether this may have affected the reported glycemic efficacy of iGlar, and the glycemic differences observed between treatment with iGlarLixi and iGlar. <b>Methods:</b> The efficacy of iGlar under uncapped conditions was simulated in a two-step approach. First, a model characterizing the relationship between iGlar dose and fasting self-measured plasma glucose (f-SMPG) was developed. Then, the relationship between glycated hemoglobin A1<sub>c</sub> (A1C) and f-SMPG was established to translate simulated f-SMPG responses to A1C responses. <b>Results:</b> Most patients achieved stable f-SMPG at ∼60 units/day, with no further reduction with increasing insulin dose. In comparisons of observed/capped and simulated/uncapped changes in mean A1C from baseline to Week 30, iGlarLixi consistently demonstrated treatment benefit compared with iGlar. Uncapping resulted in a slightly higher mean iGlar dose in both LixiLan-O (+0.72 units) and LixiLan-L (+2.1 units), without marked impact on f-SMPG or A1C change from baseline. <b>Conclusion:</b> Uncapping the iGlar dose in LixiLan-O and LixiLan-L would not have led to significant improvements in mean A1C reduction in the iGlar arm, supporting the conclusion that iGlarLixi provides additional, clinically relevant glycemic control versus iGlar alone.